Spyre Therapeutics Inc SYRE
News
Spyre Therapeutics Announces Pricing of $350.0 Million Public Offering of Common Stock
Spyre Therapeutics Announces Proposed Public Offering of its Common Stock
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics to Participate in Upcoming September Investor Conferences
Stocks to Watch: Intuit, Spyre Therapeutics, Zoom Communications, nCino
Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072
Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa
Spyre Therapeutics Announces Grants of Inducement Awards
Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

